Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial [0.03%]
抗TL1A单克隆抗体Tulisopimod治疗克罗恩病的诱导期安全性和有效性：IIa期临床试验
Brian G Feagan,Bruce E Sands,Corey A Siegel et al.
Brian G Feagan et al.
Background: TNF-like cytokine 1A (TL1A) is a key mediator of inflammation and fibrosis. The efficacy and safety of the anti-TL1A monoclonal antibody tulisokibart as induction treatment was assessed in adults with moderate...
Su Wang,Mitchell Leus,Markus Cornberg et al.
Su Wang et al.
A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profiles [0.03%]
2024年全球乙肝消除国家政策、规划和进展报告：33份乙肝消除档案概况分析结果
Lindsey Hiebert-Suwondo,Jana Manning,Rania A Tohme et al.
Lindsey Hiebert-Suwondo et al.
The Coaltion for Global Hepatitis Elimination's National Hepatitis Elimination Profiles assess the status of national data, policy, and programme development the elimination of viral hepatitis. Profiles from 33 countries and territories sho...
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial [0.03%]
特瑞普利单抗联合贝伐珠单抗对比索拉非尼一线治疗晚期肝细胞癌（HEPATORCH）：一项随机、开放标签、III期临床试验
Yinghong Shi,Guohong Han,Jian Zhou et al.
Yinghong Shi et al.
Background: Although several PD-1 or PD-L1 inhibitors combined with antiangiogenic agents have been approved as first-line treatment of advanced hepatocellular carcinoma, treatment needs remain unmet given the high incide...
A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profiles [0.03%]
2024年全球国家政策、方案和甲型肝炎消除进展报告：33个国家甲型肝炎消除档案的结果分析
Lindsey Hiebert-Suwondo,Jana Manning,Rania A Tohme et al.
Lindsey Hiebert-Suwondo et al.
The Coalition for Global Hepatitis Elimination's National Hepatitis Elimination Profiles assess the status of national data, policy, and programme development for the elimination of viral hepatitis. To date, profiles from 33 countries and t...
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study [0.03%]
前瞻性多中心胰腺导管腺癌风险患者及疑似患者的血浆多重代谢标志物验证研究（METAPAC研究）：一项分期四期的诊断性遮蔽型调查研究
Ujjwal M Mahajan,Bettina Oehrle,Elisabetta Goni et al.
Ujjwal M Mahajan et al.
Background: Earlier diagnosis of pancreatic ductal adenocarcinoma is key to improving overall survival in patients with this hard-to-treat cancer. We independently validated two previously identified plasma-based metaboli...
Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trial [0.03%]
Etrasimod治疗嗜酸性食管炎（VOYAGE）：一项双盲、安慰剂对照、随机、2期临床试验
Evan S Dellon,Margaret H Collins,Albert J Bredenoord et al.
Evan S Dellon et al.
Background: Novel treatments are needed for eosinophilic oesophagitis. Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator in development for the treatment of immune-mediated ...